HBV reactivation (HBVr) can be prevented by nucleos (t) ide analogues (NAs). We
conducted a systematic review and meta-analysis on the risk of HBVr associated with new …

Hepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but
is preventable. HBV reactivation is most commonly reported in patients receiving …

Background Cancer patients with hepatitis B virus (HBV) and hepatitis C virus (HCV)
infections are at high risk of viral reactivation after cancer treatment. However, there is a …

The evidence for chronic hepatitis B virus (HBV) infection and hepatocellular carcinoma
(HCC) occurrence is well established. The hepatocyte epithelium carcinogenesis caused by …

Background Immunotherapy shows promise as a treatment option for various cancers.
However, there is growing concern over potential complications from hepatitis B virus (HBV) …

Abstract Purpose Immune checkpoint inhibitors (ICIs) have been explored as first-line
treatment in various types of previously untreatable malignancies, while limited evidence is …

Aim The risk of hepatitis B virus (HBV) reactivation with immune checkpoint inhibitors (ICIs)
is an important issue that has not yet been fully investigated. ICI is also expected to have an …

Aim: To analyze the safety of immune checkpoint inhibitors in primary liver cancer patients
and to identify the risk factors for immune-related adverse events (irAEs). Methods: The …

Objective This study aimed to access hepatitis B virus (HBV) reactivation and its effect on
survival in HBV-related hepatocarcinoma (HCC) patients who underwent transarterial …

Background and aims Programmed cell death protein-1 (PD-1) inhibitors plus tyrosine
kinase inhibitor (TKI) have dramatically improved survival of patients with advanced …